9780470673171

Non-Alcoholic Fatty Liver Disease A Practical Guide

by ; ;
  • ISBN13:

    9780470673171

  • ISBN10:

    0470673176

  • Edition: 1st
  • Format: Hardcover
  • Copyright: 4/29/2013
  • Publisher: Wiley-Blackwell
  • Purchase Benefits
  • Free Shipping On Orders Over $59!
    Your order must be $59 or more to qualify for free economy shipping. Bulk sales, PO's, Marketplace items, eBooks and apparel do not qualify for this offer.
  • Get Rewarded for Ordering Your Textbooks! Enroll Now

Supplemental Materials

What is included with this book?

  • The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.
  • The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.

Summary

The sharp rise in cases of Non-alcoholic fatty liver disease is fast becoming one of the major concerns for hepatologists worldwide. This comprehensive clinical guide explains how to diagnose NAFLD and manage patients according to the best standards of care. Contributors from the world's leading institutions concentrate on patient care, drawing on their extensive experience.

Table of Contents

1 What is NAFLD, and why is it important?
Geoffrey C Farrell, Arthur J McCullough and Christopher P. Day

2 NAFLD in the community.
Leon Adams

3 Pathology of non-alcoholic fatty liver disease.
Elizabeth M. Brunt and David E. Kleiner

4 The natural history of NAFLD.
Paul Angulo

5 Emerging concepts on pathogenesis of NASH.
Isabelle A. Leclercq

6 Diabetes and NAFLD: why is the connection important?
Elisabetta Bugianesi

7 NAFLD and cardiovascular risk factors: implications for vascular disease.
Giovanni Targher

8 A primary care perspective of fatty liver: diagnosis, management, prescribing, and when to refer.
Shivakumar Chitturi and Geoffrey C. Farrell

9 Imaging of non-alcoholic fatty liver disease.
Takeshi Yokoo, An Tang and Claude Sirlin

10 Non-invasive methods to determine severity of NAFLD/NASH.
Vincent W-S Wong and Henry L-Y Chan

11 Fatigue, quality of life and psychosocial issues for people with NAFLD.
Julia L Newton and James Frith

12 Physical activity and cardiovascular fitness in patients with NAFLD: clinical importance and therapeutic implications.
Ingrid J Hickman, Nuala M. Byrne and Graeme A Macdonald

13 NAFLD, obesity and bariatric surgery.
Philippe Mathurin

14 Genetic predisposition to NAFLD and NASH. Implications for pathogenesis, diagnosis, prevention and management.
Quentin M. Anstee, Ann K. Daly and Christopher P. Day

15 NAFLD in children.
Ariel E. Feldstein

16 The pointy end of the NAFLD iceberg:  cirrhosis, portal hypertension, and liver failure.
Jonathon W Schwake, Dawn M Torres and Stephen A Harrison

17 Non-alcoholic fatty liver disease, hepatocellular cancer and other cancers.
Janine Graham and Helen L. Reeves

18 NAFLD in Chinese and South Asian people.
Jia-Horng Kao, Deepak Amarapurkar and Jian-Gao Fan

19 Non-alcoholic fatty liver disease in Japan.
Takeshi Okanoue, Kohichiroh Yasui and Yoshito Itoh

20 Non-alcoholic fatty liver disease in South America and hispanic people.
Helma Pinchemel Cotrim and Carla Daltro

21 Alcohol in non-alcoholic fatty liver disease. An oxymoron or a new standard of care?
Achuthan Sourianarayanane, Srinivasan Dasarathy and Arthur J. McCullough

22 Dietary factors in pathogenesis and care of patients with fatty liver disease.
Giulio Marchesini, Rebecca Marzocchi, Anna S. Sasdelli, Cristiana Andruccioli and Silvia Di Domizio

23 Metabolic factors and steatosis in patients with hepatitis B and C.
Francesco Negro

24 Drug therapy for NASH: insulin sensitizing agents (metformin and thiazolidinediones).
Mohammad S. Siddiqui and Arun J. Sanyal

25 Hepatoprotectants against fatty liver disease: antioxidants, ursodeoxycholic acid, and herbal medicines.
Anne Catherine Bürgi and Jean-François Dufour

26 Lipid modifiers and NASH: statins, ezetimibe, fibrates and other agents.
Giovanni Musso, Federica Molinaro, Elena Paschetta, Roberto Gambino and Maurizio Cassader

Index

Rewards Program

Write a Review